Diltiazem cream: Completed Phase III enrollment

Ventrus completed enrollment of 434 patients with anal fissures in a double-blind, placebo-controlled, international Phase III trial evaluating thrice-daily 2% diltiazem cream for 28 days. In May 2012, the company reported data from its first Phase III trial showing that thrice-daily 2% and 4% diltiazem cream met the primary endpoint of improving the average of worst anal pain associated with or following defecation from baseline to week 4 vs. placebo (see BioCentury, May 21, 2012). ...